Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration on Friday approved the first lung cancer immunotherapy drug for a molecularly defined subset of patients.

Merck's anti-PD-1 drug Keytruda (pembrolizumab) is indicated for advanced non-small cell lung cancer patients who have progressed despite receiving platinum-containing chemotherapy or agents targeting EGFR or ALK tumor mutations, and whose tumors are positive for PD-L1 expression.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.